Where do CJC-1295 and ipamorelin stand with the FDA?
Neither can be compounded for you by a U.S. pharmacy right now. Both were nominated for use in compounding, both were placed by the FDA in Category 2, its list of substances that may present significant safety risks, and both nominations were later withdrawn. The FDA’s Category 2 page still records the concerns it found:
- CJC-1295: possible immunogenicity, difficulty characterizing the ingredient and its impurities, and serious adverse events including increased heart rate and a systemic vasodilatory reaction. Clinical data are limited.
- Ipamorelin: serious adverse events, including a death, when it was given intravenously in a study of gut motility. Ipamorelin also remains in Category 2 for outsourcing facilities, added September 29, 2023.
Why doesn’t leaving Category 2 make them legal to compound?
Because Category 2 was never the gate. Under the FDA’s 503A rules, a pharmacy may only compound from a bulk substance that has a USP or NF monograph, is a component of an FDA-approved drug, or appears on the FDA’s 503A bulks list. CJC-1295 and ipamorelin meet none of the three. A withdrawn nomination simply means nobody is currently asking the FDA to add them. Neither has an FDA-approved label either, so there is no approved use, tested dose or manufacturing standard to fall back on.
That leaves the “research use only” market, where vials are labeled not for human consumption. No pharmacy standard covers what is in them, which is why our page on research-use-only peptides explains the risk in more detail.
How do sermorelin and tesamorelin reach the same goal?
All four target the same system: your pituitary’s release of growth hormone. CJC-1295 is a modified growth hormone releasing hormone (GHRH), and ipamorelin belongs to a separate group called growth hormone secretagogues. Sermorelin and tesamorelin are also GHRH analogues, with a legal pathway behind them.
| Type | FDA status | Compounding | At Ultimate Male | |
|---|---|---|---|---|
| CJC-1295 | GHRH analogue | Not approved | Not eligible | Not offered |
| Ipamorelin | Growth hormone secretagogue | Not approved | Not eligible | Not offered |
| Sermorelin | First 29 amino acids of GHRH | Formerly approved as Geref | Compounded by licensed pharmacies | Offered |
| Tesamorelin | Stabilized GHRH analogue | FDA-approved (Egrifta) for HIV-associated abdominal fat | Not compounded; biologic since 2020 | Offered as the approved product, off-label |
Sermorelin’s history matters here. Geref was taken off the market by its maker, and in 2013 the FDA formally determined that Geref was not withdrawn for reasons of safety or effectiveness. Tesamorelin’s label on DailyMed covers excess abdominal fat in adults with HIV; using it for body composition in other men is off-label, and your provider says so. For how the two compare, see tesamorelin vs sermorelin.
Are any of them allowed in sport?
None of them. The WADA Prohibited List names CJC-1295, sermorelin and tesamorelin as GHRH analogues and ipamorelin as a growth hormone secretagogue, all banned in and out of competition.
Related question: what about growth hormone itself?
Injecting HGH is a different legal problem with its own federal statute. Our page asking whether HGH is legal for anti-aging explains it, and our article on the FDA’s 2026 peptide decisions covers BPC-157, TB-500 and the rest of the review.
What happens if you ask Ultimate Male for CJC-1295 or ipamorelin?
You get a straight answer: we do not offer them, and we explain why. Then the conversation turns to what you were hoping they would do, whether that is better recovery, deeper sleep or less belly fat.
Labs come first, including an IGF-1 blood test to see where your growth hormone axis actually sits. If a peptide fits, sermorelin is the usual choice for recovery and sleep goals, and tesamorelin for stubborn visceral fat, with follow-up labs to keep IGF-1 in range.
